AN IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN
The present invention relates to purification process of pharmacologically active cytotoxic T lymphocyte-associated 4-immunoglobulin (CTLA4-lg) fusion protein by using three column chromatography steps that provides purified form of the fusion protein, substantially free of misfolded species, charge variants and aggregates. A method for purifying a fusion protein from a protein mixture comprising a fusion protein and high molecular weight (HMW) impurity.
1 . A method for purifying a fusion protein from a protein mixture comprising a fusion protein and high molecular weight (HMW) impurity, the purification process comprises the steps of;
a) obtaining the first fusion protein mixture from the suitable mammalian expression system and the impurities;
b) applying the first fusion protein mixture to affinity chromatography column;
c) eluting the fusion protein mixture from affinity chromatography column as second protein mixture;
d) applying the second fusion protein mixture to hydrophobic interaction chromatography column;
e) eluting the third fusion protein mixture from hydrophobic interaction chromatography column;
f) applying the third fusion protein mixture to anion exchange chromatography column;
g) eluting the fourth fusion protein mixture from anion exchange chromatography column;
wherein the eluted fusion protein is substantially free of HMW impurities and reduces more than 97% of HMW impurities.
2 . A method for purifying a fusion protein from a protein mixture comprising a fusion protein and pre-peak impurities the purification process comprises the steps of;
a) obtaining the first fusion protein mixture from the suitable mammalian expression system and the impurities;
b) applying the first fusion protein mixture to affinity chromatography column;
c) eluting the fusion protein mixture from affinity chromatography column as second protein mixture;
d) applying the second fusion protein mixture to hydrophobic interaction chromatography column;
e) eluting the third fusion protein mixture from hydrophobic interaction chromatography column;
f) applying the third fusion protein mixture to anion exchange chromatography column;
g) eluting the fourth fusion protein mixture from anion exchange chromatography column;
wherein the eluted fusion protein is substantially free of pre-peak impurities and reduces 99% or above of pre-peak impurities.
3 . The process as claimed in claim 1 , wherein the eluted fusion protein has more than 99% purity of monomer.
4 . The process as claimed in claim 1 , wherein the Hydrophobic interaction chromatography and anion exchange chromatography is performed in bind-elute mode.
5 . The process as claimed in claim 1 , wherein the second protein mixture is loaded onto hydrophobic interaction chromatography (HIC) at suitable pH selected from about 6 to about 9, preferably pH 8.0±0.2 and suitable conductivity selected from about 40 mS/cm to about 70 mS/cm.
6 . The process as claimed in claim 5 , wherein the suitable pH and/or conductivity is maintained with suitable buffer selected from Tris acetate, Sodium citrate, Acetate, Sodium chloride.
7 . The process as claimed in claim 1 , wherein the elution from hydrophobic interaction chromatography is performed at suitable pH 8.0±0.2 with buffer selected from Tris acetate, Sodium citrate, Acetate, Sodium chloride.
8 . The process as claimed in claim 1 , wherein the hydrophobic interaction chromatography resin is selected from Poros Benzyl, Butyl Toyopearl 650 M resin, Toyopearl Phenyl-650, Butyl Sepharose 6 Fast Flow, Phenyl Sepharose 6 Fast Flow, Butyl Sepharose HP, Phenyl Sepharose 6 Fast Flow high sub, Capto Phenyl high sub, and Capto Butyl impRes.
9 . The process as claimed in claim 1 , wherein the Affinity chromatography is selected from Protein A, Protein G and Protein L.
10 . The process as claimed in claim 1 , wherein the anion exchange resin is selected from Poros XQ, Poros HQ DEAE, Sepharose fast flow, Fractogel® EMD DEAE (M), Toyopearl DEAE-650, Toyopearl DEAE-650, and Nuvia Q.
11 . The process as claimed in claim 1 , wherein fusion protein mixture is loaded on to anion exchange chromatography at suitable pH selected from about 7 to about 8, preferably 7.5±0.2 maintained with suitable buffer selected from Tris acetate, sodium citrate, and Sodium chloride.
12 . The process as claimed in claim 1 , wherein the elution is performed from anion exchange chromatography with conductivity selected from 40 mS/cm to 90 mS/cm, preferably 85 mS/cm in linear gradient by increasing to elution buffer by about 9% or about 20% or about 25% or about 30%.
13 . The process as claimed in claim 12 , wherein the eluted fusion protein is collected from ascending 10 mAU to about descending 80 mAU.
14 . The process as claimed in claim 1 , wherein fusion protein is selected from CTLA4-IgG1, TNFR-IgG1, VEGF-IgG1.
15 . A pharmaceutical composition of CTLA4-IgG1 or CTLA4-Fc fusion protein comprising:
(a) substantially purified monomer of said fusion protein having purity at least 90% and HMW less than about 0.3%, measured by SE-HPLC; or
(b) substantially purified monomer of said fusion protein having purity at least 90% and pre-peak is less than about 0.1%, measured by SE-HPLC.
16 . (canceled)
17 . The process as claimed in claim 2 , wherein the eluted fusion protein has more than 99% purity of monomer.
18 . The process as claimed in claim 2 , wherein the elution from hydrophobic interaction chromatography is performed at suitable pH 8.0±0.2 with buffer selected from Tris acetate, Sodium citrate, Acetate, Sodium chloride.
19 . The process as claimed in claim 2 , wherein the hydrophobic interaction chromatography resin is selected from Poros Benzyl, Butyl Toyopearl 650 M resin, Toyopearl Phenyl-650, Butyl Sepharose 6 Fast Flow, Phenyl Sepharose 6 Fast Flow, Butyl Sepharose HP, Phenyl Sepharose 6 Fast Flow high sub, Capto Phenyl high sub, and Capto Butyl impRes.
20 . The process as claimed in claim 2 , wherein the anion exchange resin is selected from Poros XQ, Poros HQ DEAE, Sepharose fast flow, Fractogel® EMD DEAE (M), Toyopearl DEAE-650, Toyopearl DEAE-650, and Nuvia Q.
21 . The process as claimed in claim 2 , wherein fusion protein mixture is loaded on to anion exchange chromatography at suitable pH selected from about 7 to about 8, preferably 7.5±0.2 maintained with suitable buffer selected from Tris acetate, sodium citrate, and Sodium chloride.
22 . The process as claimed in claim 2 , wherein the elution is performed from anion exchange chromatography with conductivity selected from 40 mS/cm to 90 mS/cm, preferably 85 mS/cm in linear gradient by increasing to elution buffer by about 9% or about 20% or about 25% or about 30%.